A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

AIDS

Volumn 12, Issue 7, 1998, Pages

  Carr, Andrew ^a,c   Samaras, Katherine ^a   Burton, Samantha ^a   Law, Matthew ^b   Freund, Judith ^c   Chisholm, Donald J ^a   Cooper, David A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Diabetes; HIV; Lipids; Protease inhibitors

Indexed keywords

C PEPTIDE; CHOLESTEROL; FATTY ACID; GLUCOSE; INDINAVIR; INSULIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYNDROME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; INDINAVIR; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; NELFINAVIR; RISK FACTORS; RITONAVIR; SAQUINAVIR; SYNDROME;

EID: 0032493043     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199807000-00003     Document Type: Article

References (22)

1. Danner SA, Carr A, Leonard J, et al.: Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
2. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
4. BHIVA Guidelines Co-ordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
5. Deeks SG, Smith M, Holodny M, Kahn JO: HIV-1 protease inhibitors: a review for clinicians. JAMA 1997, 277:145-153.
6. Carr A, Brown D, Cooper DA: Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor [letter]. AIDS 1997, 11:1657-1658.
7. Grunfeld C, Feingold KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:329-337.
8. Paton NI, Macallan DC, Jebb SA, et al.: Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. J Acquir Immune Defic. Syndr Hum Retrovirol 1997, 14:119-127.
9. Lumpkin MM: Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus Infection. sFDA Public Health Advisory; 11 June 1997.
10. Dube MP, Johnson DL, Currier JS, Leedom JM: Protease inhibitor-associated hyperglycaemia [letter]. Lancet 1997, 350:713-714.
11. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Tokonaga K: Pathophysiology and pathogenesis of visceral fat obesity. Ann NY Acad Sci 1995, 748:399-406.
12. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ: Abdominal fat and insulin resistance in normal and over-weight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996, 45:633-630.
13. Nguyen T, Howard G, Kelly P, Eisman J: Bone mass, lean mass and fat mass: same gene or same environment? Am J Epidemiol 1998, 147:3-16.
14. Wick J: Guide to Exercise, Canberra: National Heart Foundation of Australia; 1983.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treaeher DF, Turner RC: Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Jensen MD, Kanaley JA, Reed JE, Sheedy PF: Measurement of abdominal and visceral fat with computed tomography and dual-energy X-ray absorptiometry. Am J Clin Nath 1995, 61:274-278.
17. Schmitz-Peiffer C, Browne CL, Oakes ND, et al.: Alterations in the expression and cellular localisation of protein kinase C isozymes ε and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997, 46:169-178.
18. Randle PJ, Garland PB, Hales CN, Newholme EA: The fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, i:785-789.
19. Jenkins AB, Storlien LH, Chisholm DJ, Kraegen EW: Effects of nonesterified fatty acid availability on tissue-specific glucose utilisation in rats in vivo. J Clin Invest 1988, 82:293-299.
20. Heyligenberg R, Romijn JA, Hommes MJ, Endert E, Eeftinck-Schattenkerk JK, Sauerwein HP: Non-insulin-mediated glucose uptake in human immunodeficiency virus-infected men. Clin Sci 1993, 84:209-216.
21. Carr A, Marriott D, Field A, Vasak E, Cooper DA: Combination antiretroviral therapy of HIV-associated microsporidiosis and cryptosporidiosis. Lancet 1998, 351:256-261.
22. 3. JAMA 1998 (in press).